Compare Stocks: CAPR, ABCL, TRLV, and RXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$5.71	$6.15	$2.74 ▼ $8.44	$1.74B	1.14	5.49 million shs	4.99 million shs
CAPR Capricor Therapeutics	$3.85	$23.00	$2.96 ▼ $40.37	$222.95M	0.54	5.34 million shs	7.27 million shs
RXRX Recursion Pharmaceuticals	$3.00	$3.32	$2.77 ▼ $7.18	$1.59B	1.03	21.90 million shs	15.28 million shs
TRLV Trulieve Cannabis	$8.62 -0.4%	$0.00	$4.19 ▼ $13.28	$1.66B	N/A	641,277 shs	711,430 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+7.53%	-29.59%	+28.89%	+34.67%
CAPR Capricor Therapeutics	0.00%	-80.46%	-83.41%	-87.54%	-51.27%
RXRX Recursion Pharmaceuticals	0.00%	+1.35%	-21.05%	-11.50%	-47.18%
TRLV Trulieve Cannabis	0.00%	+2.95%	-11.39%	+861,899,900.00%	+861,899,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$5.71	$6.15	$2.74 ▼ $8.44	$1.74B	1.14	5.49 million shs	4.99 million shs
CAPR Capricor Therapeutics	$3.85	$23.00	$2.96 ▼ $40.37	$222.95M	0.54	5.34 million shs	7.27 million shs
RXRX Recursion Pharmaceuticals	$3.00	$3.32	$2.77 ▼ $7.18	$1.59B	1.03	21.90 million shs	15.28 million shs
TRLV Trulieve Cannabis	$8.62 -0.4%	$0.00	$4.19 ▼ $13.28	$1.66B	N/A	641,277 shs	711,430 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+7.53%	-29.59%	+28.89%	+34.67%
CAPR Capricor Therapeutics	0.00%	-80.46%	-83.41%	-87.54%	-51.27%
RXRX Recursion Pharmaceuticals	0.00%	+1.35%	-21.05%	-11.50%	-47.18%
TRLV Trulieve Cannabis	0.00%	+2.95%	-11.39%	+861,899,900.00%	+861,899,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$8.00	40.11% Upside
CAPR Capricor Therapeutics	1.91	Reduce	$29.15	657.14% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.10	170.00% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	74.03% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ABCL, TRLV, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50
7/30/2026	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/28/2026	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00
7/27/2026	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/27/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/27/2026	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00
7/27/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$10.00
7/20/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$15.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$79.21M	22.01	N/A	N/A	$3.23 per share	1.77
CAPR Capricor Therapeutics	$22.27M	10.01	N/A	N/A	$5.53 per share	0.70
RXRX Recursion Pharmaceuticals	$74.68M	21.29	N/A	N/A	$2.14 per share	1.40
TRLV Trulieve Cannabis	$1.17B	1.42	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.48	N/A	N/A	N/A	-181.75%	-14.86%	-10.62%	8/5/2026 (Confirmed)
CAPR Capricor Therapeutics	-$105.04M	-$2.32	N/A	N/A	N/A	N/A	-59.27%	-48.65%	8/11/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.20	N/A	N/A	N/A	-842.95%	-54.33%	-40.60%	8/5/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CAPR, ABCL, TRLV, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.58	N/A	N/A	N/A	$2.08 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1443	N/A	N/A	N/A	$7.85 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	N/A	N/A	N/A	$10.97 million	N/A
5/12/2026	Q1 2026	CAPR Capricor Therapeutics	-$0.55	-$0.59	-$0.04	-$0.59	$40.00 million	N/A
5/11/2026	Q1 2026	ABCL AbCellera Biologics	-$0.22	-$0.14	+$0.08	-$0.14	$5.41 million	$8.32 million
5/6/2026	Q1 2026	RXRX Recursion Pharmaceuticals	-$0.30	-$0.22	+$0.08	-$0.22	$15.78 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	14.05	14.05
CAPR Capricor Therapeutics	N/A	8.42	8.42
RXRX Recursion Pharmaceuticals	0.01	5.47	5.47
TRLV Trulieve Cannabis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CAPR Capricor Therapeutics	21.68%
RXRX Recursion Pharmaceuticals	89.06%
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
CAPR Capricor Therapeutics	9.20%
RXRX Recursion Pharmaceuticals	6.65%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	305.38 million	218.65 million	Optionable
CAPR Capricor Therapeutics	101	57.91 million	52.58 million	Optionable
RXRX Recursion Pharmaceuticals	400	529.91 million	494.67 million	Optionable
TRLV Trulieve Cannabis	9,000	192.31 million	N/A	N/A

CAPR, ABCL, TRLV, and RXRX Headlines

Recent News About These Companies

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Large Growth in Short Interest

July 28, 2026 | marketbeat.com

Cantor Fitzgerald Begins Coverage on Trulieve Cannabis (NYSE:TRLV)

July 20, 2026 | marketbeat.com

Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida

July 16, 2026 | prnewswire.com

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Significant Growth in Short Interest

July 14, 2026 | marketbeat.com

Why Is Trulieve (NYSE:TRLV) Expanding Its NYSE Presence?

July 13, 2026 | kalkinemedia.comK

Two marijuana MSOs named among ‘America’s Best Companies’

July 10, 2026 | mjbizdaily.comM

Trulieve Cannabis Corp. to Hold Second Quarter 2026 Results Conference Call on August 7, 2026

July 10, 2026 | prnewswire.com

Trulieve Named to TIME's America's Best Companies 2026 List

July 10, 2026 | prnewswire.com

Better Cannabis Growth Stock: Trulieve or Vireo Growth

July 10, 2026 | fool.com

Trulieve (NYSE:TRLV) NYSE Listing Redefines Cannabis Market Access

July 8, 2026 | kalkinemedia.comK

Trulieve targets September opening for 3 Texas MMJ stores

July 7, 2026 | mjbizdaily.comM

Trulieve Cannabis (NYSE:TRLV) Opens a New Market Era

July 7, 2026 | kalkinemedia.comK

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

July 7, 2026 | money.usnews.com

MSOS Hits a 2026 High as Cannabis Stocks Brace for DEA's July 15 Rescheduling Deadline

July 3, 2026 | investorideas.comI

Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale

July 1, 2026 | prnewswire.com

Trulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One Year

June 27, 2026 | fool.com

Trulieve Cannabis (NYSE:TRLV) CEO Sells 136,811 Shares

June 27, 2026 | insidertrades.com

Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan

June 26, 2026 | prnewswire.com

TRLV PE / PEG Ratio

June 26, 2026 | seekingalpha.com

Insider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in Stock

June 26, 2026 | insidertrades.com

TRLV Trulieve Cannabis Corp.

June 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ABCL, TRLV, and RXRX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$5.71 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.74 +0.03 (+0.51%)

As of 07/31/2026 07:57 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Capricor Therapeutics NASDAQ:CAPR

$3.85 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.88 +0.02 (+0.65%)

As of 07/31/2026 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.00 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.00 0.00 (-0.17%)

As of 07/31/2026 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Trulieve Cannabis NYSE:TRLV

$8.62 -0.03 (-0.36%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$8.55 -0.07 (-0.80%)

As of 07/31/2026 07:56 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ABCL, TRLV, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ABCL, TRLV, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ABCL, TRLV, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ABCL, TRLV, and RXRX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Capricor Therapeutics NASDAQ:CAPR

Recursion Pharmaceuticals NASDAQ:RXRX

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ABCL, TRLV, and RXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ABCL, TRLV, and RXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ABCL, TRLV, and RXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ABCL, TRLV, and RXRX Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Capricor Therapeutics NASDAQ:CAPR

Recursion Pharmaceuticals NASDAQ:RXRX

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools